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Background
Prior to the rollout of potent antiretroviral therapy
(ART), Kaposi’s sarcoma (KS) was the most commonly
reported malignancy in many resource-limited settings,
such as most of sub-Saharan Africa. In resource-replete
s e t t i n g s( e . g . ,U . S .o rE u r o p e ) ,t h ea d v e n to fA R T —and
the availability of established research networks—
resulted in documentation of a marked decrease in KS
incidence. In contrast, in resource-limiting settings like
Africa, the heretofore lack of epidemiologic infrastruc-
ture has limited our knowledge about the effect of ART
on KS incidence.
Methods
We prospectively followed HIV-infected adults, without
prior KS, attending 26 HIV/AIDS clinics at the Mbarara
(Uganda) or AMPATH (Kenya) sites of East Africa
IeDEA. Time zero was October 2008, when we intro-
duced skin punch biopsy for KS diagnosis, which was
available same-day free of charge. Biopsies were adjudi-
cated by board-certified UCSF dermatopathologists.
Patients were followed until they developed KS, death,
loss-to-follow-up, or administrative closure. Once
started on ART, patients were considered on ART irre-
spective of adherence/interruptions. Incident KS was
defined as any new occurrence of KS 30 days after clinic
enrollment that was documented either pathologically
or by clinical diagnosis in the absence of pathology.
Results
We followed 98,024 HIV-infected adults: 31% men, 66%
ever on ART, and median values at study enrollment of
35 years old (IQR: 29-43) and 277 CD4+ T-cells/mm
3
(IQR: 137-453). Patients were followed for 144,182 per-
son-years (median 1.8 years/patient) for 499 incident KS
diagnoses, 43% of which were pathologically confirmed.
KS incidence during non-ART use was 1876 cases/
100,000-person-years in Uganda and 596 in Kenya; inci-
dence during ART use was 201/100,000-person-years in
Uganda and 270 in Kenya. After adjustment for age and
gender, ART-users had a substantially reduced rate of
KS compared to non-users: 88% reduction in Uganda
(p<0.001), and 50% in Kenya (p<0.001). Further adjust-
ment by CD4+ count showed a persistent ART effect,
suggesting ART benefits for KS prevention above and
beyond CD4 restoration (Table). In ART-users who
achieved a CD4+ count of >350 cells/mm
3, KS incidence
declined to 18/100,000-person-years in Uganda and 93/
100,000-person-years in Kenya. * Correspondence: martin@psg.ucsf.edu
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In a prospective study in East Africa, KS incidence was
very high in untreated HIV-infected adults but was sub-
stantially reduced by ART — similar to that observed in
resource-replete settings. Despite ART, absolute rates of
KS remained considerable until a CD4+ count of >350
was achieved, suggesting the need for earlier ART initia-
tion. The IeDEA platform provides unique opportunities
for prospective African KS research.
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Table 1
KS Incidence During Non-ART Use and ART Use in East African HIV-infected Adults
During Time of No ART Use During ART Use
CD4+ T cell count
(cells/mm
3)
No. KS cases Person-years Rate
(95% CI)*
No. KS cases Person-years Rate
(95% CI)*
0-50 19 645 2943 (1877, 4615) 62 4070 1523 (1187, 1954)
51-100 2 613 326 (81, 1304) 37 5166 716 (518, 988)
101-200 8 1682 475 (237, 951) 45 15651 287 (214, 385)
201-350 27 6383 423 (290, 616) 40 27035 147 (108, 201)
>350 23 13926 165 (109, 248) 31 37804 82 (57, 116)
* per 100,000 person-years
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